By Stephen Nakrosis


Gyre Therapeutics on Tuesday said China's National Medical Products Administration approved the company's avatrombopag maleate tablets to treat certain patients with thrombocytopenia.

The treatment was approved for those with the condition associated with chronic liver disease in adults undergoing elective diagnostics procedures or therapy, Gyre said.

Thrombocytopenia can result in a lower platelet count in a person's blood.

Gyre said it acquired avatrombopag under a transfer agreement with Nanjing Healthnice Pharmaceutical Technology in June 2021. Avatrombopag was approved by the Food and Drug Administration to treat adults with CLD-associated thrombocytopenia in May 2018. Its indication was expanded to include the treatment of immune thrombocytopenia in June 2019.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

07-02-24 1647ET